This grant is for advancing cervical cancer prevention and treatment strategies for women living with HIV. The HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network will conduct pragmatic clinical trials to evaluate innovative approaches that reduce failures in the cervical cancer screening and treatment cascade. Focus areas include increasing screening uptake, improving management of screen positives, and optimizing precancer treatments. The objective is to provide crucial evidence to refine clinical practice guidelines and inform public health policy, ultimately improving cervical cancer prevention implementation programs. The Coordinating Center will manage all network activities, including concept/protocol review, centralized data management, and independent auditing.
Opportunity ID: 336276
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-21-045 |
| Funding Opportunity Title: | Coordinating Center for HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network (U24 Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Oct 26, 2021 |
| Last Updated Date: | Oct 26, 2021 |
| Original Closing Date for Applications: | Dec 28, 2021 |
| Current Closing Date for Applications: | Dec 28, 2021 |
| Archive Date: | Feb 02, 2022 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $750,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Public and State controlled institutions of higher education State governments For profit organizations other than small businesses County governments City or township governments Small businesses Private institutions of higher education Others (see text field entitled “Additional Information on Eligibility” for clarification) Special district governments Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Native American tribal governments (Federally recognized) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Public housing authorities/Indian housing authorities |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | The HIV/Cervical Cancer Prevention ‘CASCADE’ Clinical Trials Network seeks to evaluate innovative approaches for overcoming barriers and reducing failures in the cervical cancer screening and treatment cascade for women living with HIV. The proposed multicenter network will conduct pragmatic clinical trials to evaluate the effectiveness of clinically proven interventions in intended-use settings with a goal to optimize the cervical cancer screening, management, and precancer treatment cascade for women living with HIV. These trials will focus on the health care continuum for secondary cervical cancer prevention, i.e., increasing screening uptake, improving management of screen positives, facilitating precancer treatment access, and optimizing precancer treatments. Data from these trials will be used to provide the necessary evidence to refine clinical practice guidelines and inform public health policy with a goal to generate crucial actionable evidence for improving cervical cancer prevention implementation programs. The U24 cooperative agreement mechanism-funded Network Coordinating Center will coordinate all network activities, including concept and protocol review processes, provide centralized data management support, conduct independent clinical trials auditing for the network trials, and interface with network grantees for augmenting study training, reporting, and quality assurance activities. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-045.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or after January 25, 2022 | PKG00269587 | Nov 28, 2021 | Dec 28, 2021 | View | |
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00269481 | Nov 28, 2021 | Jan 24, 2022 | View |
Package 1
Mandatory forms
336276 RR_SF424_5_0-5.0.pdf
336276 PHS398_CoverPageSupplement_5_0-5.0.pdf
336276 RR_OtherProjectInfo_1_4-1.4.pdf
336276 PerformanceSite_4_0-4.0.pdf
336276 RR_KeyPersonExpanded_4_0-4.0.pdf
336276 RR_Budget_3_0-3.0.pdf
336276 PHS398_ResearchPlan_4_0-4.0.pdf
336276 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
336276 RR_SubawardBudget30_3_0-3.0.pdf
336276 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
336276 RR_SF424_2_0-2.0.pdf
336276 PHS398_CoverPageSupplement_5_0-5.0.pdf
336276 RR_OtherProjectInfo_1_4-1.4.pdf
336276 PerformanceSite_2_0-2.0.pdf
336276 RR_KeyPersonExpanded_2_0-2.0.pdf
336276 RR_Budget_1_4-1.4.pdf
336276 PHS398_ResearchPlan_4_0-4.0.pdf
336276 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
336276 RR_SubawardBudget30_1_4-1.4.pdf
336276 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
